Steel Dynamics Inc. vs TG Therapeutics Inc — how do they compare? Steel Dynamics Inc. trades at $238.38 (market cap $33.57B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Steel Dynamics Inc. is far larger — about 4.1× TG Therapeutics Inc's market cap, and Steel Dynamics Inc. pays a 0.91% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Steel Dynamics Inc. for 1 Days and TG Therapeutics Inc for 16 Days on average.
| STLD | TGTX | |
|---|---|---|
Market Cap | $33.57B | $8.16B |
Volume | 852,460 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $282.76 | $59.06 |
52-Week Low | $141.23 | $26.94 |
Typical Hold Time | 1 Days | 16 Days |
Enterprise Value | $37.18B | $8.37B |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Steel Dynamics produces steel, processes recycled metals, and provides steel-fabrication services. Its operations use recycled scrap as a key input and also include aluminum products.
Read more on STLD →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →